Rudick Richard Alan
Known title: DirectorCIK: 0001975263
Rudick Richard Alan's purchase track record
Rudick Richard Alan has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2025 | IMUX | $100K | +9.4% | -10.7% | +14.4% |
| 11/12/2024 | IMUX | $100K | -17.4% | -13.9% | -1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMUX | ▲ Buy | Open Market | 143,075 | $100K | 6/3/2025 | View on chart |
| IMUX | ▲ Buy | Open Market | 87,300 | $100K | 11/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Immunic Presents Four Abstracts at MSToronto2026
Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.
Immunic Presents Four Abstracts at MSToronto2026. Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.